Conference Correspondent

In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65. Read More ›

Addition of venetoclax to bortezomib/dexamethasone in relapsed/refractory multiple myeloma patients (BELLINI phase 3 study) improves progression-free survival, but also results in higher mortality, with t(11;14) or BCL2high gene expression patients benefiting most. Read More ›

In the DREAMM-2 study of belantamab mafodotin in heavily pretreated relapsed/refractory multiple myeloma patients, comparable overall response rates (~30%) were observed between patients who had 3 to 6 prior therapies and those with ≥7. Read More ›

Melflufen/dexamethasone demonstrated meaningful activity and manageable safety profile in patients with relapsed/refractory multiple myeloma who had ≥2 prior lines of therapy and were also refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Read More ›

Immune-related adverse events did not affect the clinical benefit of consolidation checkpoint inhibitor therapy after chemoradiation in stage III non–small-cell lung cancer. Read More ›

The frequency and durability of outcomes associated with acquired resistance to PD-1 inhibition in non–small-cell lung cancer are presented. Read More ›

The characteristics of long-term responders to PD-1 blockade are presented. Read More ›

For oncologists and others who advocate for smoking cessation, it is important to know whether recent quitters who are diagnosed with lung cancer can achieve a survival benefit. Read More ›

Weekly epirubicin was evaluated as a potential “gentle” option for second-line chemotherapy in patients with malignant pleural mesothelioma after failure of first-line pemetrexed-based chemotherapy. Read More ›

Approximately 30% of patients with non–small-cell lung cancer present with early-stage (I-IIIA) disease and undergo surgery. Researchers assessed the use of adjuvant osimertinib in this population. Read More ›

Page 3 of 16

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: